Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Medtronic
McKinsey
Moodys
AstraZeneca

Last Updated: May 25, 2022

Clovis Oncology Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Clovis Oncology Inc
International Patents:249
US Patents:12
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Clovis Oncology Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No 7,351,701 See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes 9,987,285 See Plans and Pricing Y See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No 9,861,638 See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes 7,531,530 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Clovis Oncology Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1633724 122015000025 Germany See Plans and Pricing PRODUCT NAME: OLAPARIB, SOWIE SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
1633724 PA2015016 Lithuania See Plans and Pricing PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
2534153 18C1049 France See Plans and Pricing PRODUCT NAME: CAMSYLATE DE RUCAPARIB; NAT. REGISTRATION NO/DATE: EU/1/17/1250 20180529; FIRST REGISTRATION: - EU/1/17/1250 20180529
2534153 2018/043 Ireland See Plans and Pricing PRODUCT NAME: RUCAPARIB CAMSYLATE; REGISTRATION NO/DATE: EU/1/17/1250 20180524
2534153 300958 Netherlands See Plans and Pricing PRODUCT NAME: RUCAPARIB CAMSYLAAT; REGISTRATION NO/DATE: EU/1/17/1250 20180529
1633724 C20150012 00136 Estonia See Plans and Pricing PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
AstraZeneca
Johnson and Johnson
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.